Tenvir AF 25 mg (Tenofovir Alafenamide) — Product Description

Tenvir AF is a Cipla preparation containing tenofovir alafenamide (TAF) 25 mg — the modern prodrug of tenofovir with dramatically better renal and bone safety profile than the older tenofovir disoproxil fumarate (TDF). The product is supplied as film-coated tablets and is used in antiviral therapy for HIV-1 infection and chronic hepatitis B under medical supervision.

• Active ingredient: Tenofovir alafenamide 25 mg per tablet
• Pack: 30 film-coated tablets
• Manufacturer: Cipla (India)

Both forms are tenofovir prodrugs, but they differ fundamentally in how they deliver the active drug to cells:

• TDF circulates in plasma at high levels — the kidneys and bones are exposed to significant drug concentrations, which can cause renal decline and decreased bone mineral density over years of therapy;
• TAF is taken up efficiently by lymphoid and liver cells — active tenofovir reaches its target at ~10-fold lower plasma concentration, dramatically reducing renal and bone exposure;
• Clinical trials (GS-104, GS-111 and successors) documented stable kidney function and bone density with TAF versus measurable decline with TDF.

This is why modern HIV and HBV guidelines favor TAF-based regimens — and why patients on long-term therapy ask to switch to TAF.

Tenvir AF is prescribed by physicians for:

• HIV-1 infection — as a component of combination antiretroviral therapy (in fixed-dose combinations with emtricitabine/entecavir partners, or standalone in approved regimens);
• chronic hepatitis B in adults — monotherapy or combination, determined by the hepatologist/infectiologist;

The medication is prescription-only. Therapy duration, regimen and monitoring are determined by the treating physician.

• Standard dose: 1 tablet (25 mg) once daily, with food (enhances absorption);
• Same time each day; adherence is critical — missed doses drive resistance;
• Do not stop abruptly: hepatitis B reactivation risk on discontinuation requires medical supervision;
• Regular monitoring: renal function (creatinine, phosphate), bone density at physician discretion, viral load per schedule.

• Modern TAF prodrug — improved renal and bone safety vs TDF;
• Original Cipla product (India's major WHO-qualified manufacturer);
• Once-daily oral regimen;
• Dual indication: HIV-1 and chronic hepatitis B;
• Suitable for long-term therapy under medical supervision.

The most commonly reported adverse reactions (generally milder than TDF):

• nausea, abdominal discomfort (typically early, transient);
• headache;
• rare: renal biomarker changes, lipid parameter shifts (monitored by the physician).

Medical attention should be sought for significant fatigue, persistent nausea/vomiting, or signs of lactic acidosis (uncommon but a class warning for nucleoside analogs).

• Hypersensitivity to tenofovir alafenamide or any component;
• Concomitant use with other tenofovir-containing products (duplicate therapy);
• Specific drug interactions (rifampicin, St. John's Wort, certain anticonvulsants) — physician review required.

Pregnancy and breastfeeding decisions are made individually by the treating physician — TAF is used in pregnancy in specific scenarios under specialist guidance.

FAQ — Frequently Asked Questions

What is the difference between Tenvir AF (TAF) and Tenvir (TDF)?

Both contain tenofovir, but Tenvir AF is the alafenamide prodrug: it delivers the active drug into cells at ~10-fold lower plasma levels, sparing kidneys and bones. Long-term TDF therapy can cause renal decline and bone loss; TAF was developed specifically to avoid this. Guidelines increasingly prefer TAF, especially for patients with kidney risk factors.

Is Tenvir AF the same as Descovy?

Same active molecule — tenofovir alafenamide 25 mg. Descovy (Gilead) combines TAF with emtricitabine in a fixed-dose tablet; Tenvir AF is TAF standalone, allowing the physician to pair it with different partners. Cipla is the Indian manufacturer; Gilead is the US originator.

Can Tenvir AF cure HIV or hepatitis B?

No — neither is curable with current antivirals. Tenvir AF suppresses viral replication long-term, preserving immune function (HIV) and preventing liver progression (HBV). Continuous adherence under medical supervision is essential.

Do I need regular tests during therapy?

Yes — this is standard practice: viral load (HIV/HBV), renal function and phosphorus periodically, bone density at physician discretion for long-term therapy. Your physician sets the schedule.

What if I miss a dose?

Take it as soon as you remember the same day. Never double the dose. Consistent daily adherence is the foundation of antiviral success — missing doses can lead to resistance.

Ask a question or inquire about delivery to your country

Telegram

WhatsApp